Advanced Search Results

Click here to go to the Global Anti-Bribery Guidance website.       Corporate Political Engagement 2018: Rating Private Sector Political Transparency (November 2018)               Incentivising Ethics: Managing Incentives to Encourage Good and Deter Bad Behaviour (October 2016)               Managing Third Party R

  The Transparency International Corporate Anti-Corruption Benchmark is a comprehensive tool that measures and compares the performance of anti-corruption programmes across companies. The methodology is based on Transparency International’s extensive anti-corruption expertise and understanding of best practice for the private sector, combined with input from experiences specialist in-house

  COVID-19 UPDATE: Due to the current coronavirus pandemic we have made contingency measures to take our Business Integrity Forum and Corporate Anti-Corruption Benchmark events online until further notice. This will not affect the quality or frequency of the events and we see the events being in this format as a chance to broaden the

Corruption within the pharmaceutical and healthcare sectors is a matter of life and death. It has a corrosive impact on health, negatively impacting public health budgets, the price of health services and medicines, and ultimately the quality of care dispensed. Reports estimate that as much as 6% of annual global health expenditure is lost to corruption

Click here to go to the Global Anti-Bribery Guidance website.       Corporate Political Engagement 2018: Rating Private Sector Political Transparency (November 2018)               Incentivising Ethics: Managing Incentives to Encourage Good and Deter Bad Behaviour (October 2016)               Managing Third Party R

Transparency International's guidance provides specific, practical advice based on real-life experience on how to conduct an effective bribery risk assessment.

The Government announced last year that it would publish its first-ever National Anti-Corruption Action Plan. Since TI first proposed this idea five years ago, we have been arguing that the Government should draw up such a plan, and we are delighted that it is now happening.

Robert Barrington and Will Kenyon discuss some of the challenges facing companies and why conducting an effective bribery risk assessment is necessary.

In the past few days, we have seen two high-profile corruption stories emanating from China – the allegations against GlaxoSmithKline (GSK) and the indictment of high-profile regional governor Bo Xilai. What should we make of them?